natgillin/translations-raw huggingface dataset:
The corresponding frequencies in the control group receiving chemotherapy alone were 1.1% vs. 0.8%, respectively. 
V kontrolni skupini, ki je prejemala samo kemoterapijo, je bila pogostnost tega neželenega učinka 1,1 % v primerjavi z 0,8 %.
Zirabev is a biosimilar medicinal product. 
Zdravilo Zirabev je podobno biološko zdravilo.
Sepsis, Cellulitis, Abscess a,b 
Infekcijske in parazitske bolezni sepsa, celulitis, absces a,b
Prior radiation is a risk factor for GI perforation in patients treated for persistent, recurrent or metastatic cervical cancer with bevacizumab and all patients with GI perforation had a history of prior radiation. 
Predhodno obsevanje je dejavnik tveganja za perforacijo prebavil pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu, ki se zdravijo z bevacizumabom; vse bolnice s perforacijami prebavil so se predhodno zdravile z obsevanjem.
Each pack of Zirabev contains one vial. 
Vsako pakiranje zdravila Zirabev vsebuje 1 vialo.
The first infusion will be given to you over 90 minutes. 
Prva infuzija bo trajala 90 minut.
Patients receiving bevacizumab plus chemotherapy, with a history of arterial thromboembolism, diabetes or age greater than 65 years have an increased risk of developing arterial thromboembolic reactions during therapy. 
Pri bolnikih, ki prejemajo bevacizumab skupaj s kemoterapijo in imajo v anamnezi arterijsko trombembolijo, sladkorno bolezen ali so starejši od 65 let, obstaja med zdravljenjem povečano tveganje za pojav arterijskih trombemboličnih dogodkov.
Necrotising fasciitis, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation (rare) (see also section 4.4) 
Infekcijske in parazitske bolezni nekrotizirajoči fasciitis, ki je običajno posledica zapletov pri celjenju ran, perforacije prebavil ali nastanka fistule (redko) (glejte tudi poglavje 4.4)
In a randomized phase II study (BO20924) a total of 154 patients aged ≥ 6 months to <18 years with newly diagnosed metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma were treated with standard of care (Induction IVADO/IVA+/- local therapy followed by Maintenance Vinorelbine and cyclophosphamide) with or without bevacizumab (2.5 mg/kg/week) for a total duration of treatment of approximately 18 months. 
V randomizirani študiji 2. faze (BO20924) je skupno 154 bolnikov, starih od ≥ 6 mesecev do < 18 let, z novo diagnosticiranim metastatskim rabdomiosarkomom in drugimi vrstami sarkoma mehkega tkiva prejemalo standardno zdravljenje (indukcija z IVADO/IVA z lokalnim zdravljenjem ali brez njega, čemur je sledilo vzdrževalno zdravljenje z vinorelbinom in ciklofosfamidom) z bevacizumabom ali brez njega (2,5 mg/kg/teden) v približno 18-mesečnem obdobju celotnega zdravljenja.
Addition of bevacizumab to RT/T did not demonstrate clinical benefit in study BO25041 in 60 evaluable children patients with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high- grade glioma (HGG) (see section 4.2 for information on paediatric use). 
V študiji BO25041 dodajanje bevacizumaba k RT/T ni pokazalo klinične koristi pri 60 pediatričnih bolnikih z novo diagnosticiranim supratentorialnim ali infratentorialnim cerebelarnim ali pedunkularnim gliomom visoke stopnje (HGG), ki jih je bilo mogoče oceniti (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Chemical and physical in-use stability has been demonstrated for 48 hours at 2°C to 30°C in sodium chloride 9 mg/ml (0.9%) solution for injection. 
Kemijsko in fizikalno stabilnost v 0,9-odstotni (9 mg/ml) raztopini natrijevega klorida za injiciranje med uporabo so dokazali za čas do 48 ur pri temperaturi od 2 °C do 30 °C.
Name and address of the manufacturer responsible for batch release Pfizer Ireland Pharmaceuticals 
Ime in naslov izdelovalca, odgovornega za sproščanje serij> Pfizer Ireland Pharmaceuticals Grange Castle Business Park
Patients with histologically confirmed mCRC and disease progression were randomised 1:1 within 3 months after discontinuation of bevacizumab first-line therapy to receive fluoropyrimidine/oxaliplatin- or fluoropyrimidine/irinotecan-based chemotherapy (chemotherapy switched depending on first-line chemotherapy) with or without bevacizumab. 
Bolnike s histološko potrjenim mCRC in napredovanjem bolezni so v 3 mesecih po prekinitvi zdravljenja z bevacizumabom v prvi liniji randomizirali v razmerju 1 : 1 na kemoterapijo na osnovi fluoropirimidina in oksaliplatina ali kemoterapijo na osnovi fluoropirimidina in irinotekana (kemoterapijo so zamenjali glede na prvo linijo kemoterapevtskega zdravljenja) z bevacizumabom ali brez njega.
The incidence of these reactions in some clinical trials of bevacizumab is common (up to 5% in bevacizumab- treated patients). 
V nekaterih kliničnih preskušanjih bevacizumaba je bila pojavnost teh reakcij pogosta (največ 5 % pri bolnikih, ki so se zdravili z bevacizumabom).
Grade 3-5 (NCI-CTCAE v.3) venous thromboembolic reactions have been reported in up to 7.8% of patients treated with chemotherapy plus bevacizumab compared with up to 4.9% in patients treated with chemotherapy alone (across indications, excluding persistent, recurrent, or metastatic cervical cancer). 
O venskih trombemboličnih dogodkih stopnje 3-5 (NCI-CTCAE v.3) so poročali pri največ 7,8 % bolnikov, ki so se zdravili s kemoterapijo in bevacizumabom, v primerjavi z največ 4,9 % pri bolnikih, ki so se zdravili samo s kemoterapijo (pri vseh indikacijah, razen pri dolgotrajnem, ponavljajočem se ali metastatskem raku materničnega vratu).
The primary efficacy parameter of the trial was the duration of progression-free survival. 
Primarni parameter učinkovitosti v preskušanju je bilo trajanje preživetja brez napredovanja bolezni.
Clear to slightly opalescent, colourless to pale brown liquid. 
bistra do rahlo motna, brezbarvna do svetlo rjava tekočina
• AVF2107g: A weekly schedule of irinotecan/bolus 5-fluorouracil/folinic acid (IFL) for a total of 4 weeks of each 6 week-cycle (Saltz regimen). 
AVF2107g: tedenska shema irinotekana, bolusa 5-fluorouracila in folinske kisline (IFL), skupaj 4 tedne v vsakem 6-tedenskem ciklu (shema Saltz).
In bevacizumab clinical trials, gastrointestinal fistulae (all grade) have been reported with an incidence of up to 2% in patients with metastatic colorectal cancer and ovarian cancer, but were also reported less commonly in patients with other types of cancer. 
V kliničnih preskušanjih bevacizumaba so poročali o fistulah prebavil (vseh stopenj) s pojavnostjo največ 2 % pri bolnikih z metastatskim rakom debelega črevesa in danke in bolnicah z rakom jajčnikov, pri bolnikih z drugimi vrstami raka pa so o njih poročali redkeje.
Gastrointestinal perforations have been reported in clinical trials with an incidence of less than 1% in patients with non-squamous non-small cell lung cancer, up to 1.3% in patients with metastatic breast cancer, up to 2.0% in patients with metastatic renal cell cancer or in patients with ovarian cancer, and up to 2.7% (including gastrointestinal fistula and abscess) in patients with metastatic colorectal cancer. 
V kliničnih preskušanjih so poročali o perforaciji prebavil s pojavnostjo manj kot 1 % pri bolnikih z neploščatoceličnim nedrobnoceličnim rakom pljuč, največ 1,3 % pri bolnikih z metastatskim rakom dojk, največ 2,0 % pri bolnikih z metastatskim rakom ledvičnih celic ali pri bolnicah z rakom jajčnikov ter največ 2,7 % (vključno z fistulo prebavil in abscesom) pri bolnikih z metastatskim rakom debelega črevesa in danke.
Posterior reversible encephalopathy syndrome (PRES) (see section 4.8) There have been rare reports of bevacizumab-treated patients developing signs and symptoms that are consistent with PRES, a rare neurologic disorder, which can present with the following signs and symptoms among others: seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. 
Pri bolnikih, ki so se zdravili z bevacizumabom, so redko poročali o pojavu znakov in simptomov, značilnih za PRES, redko nevrološko motnjo, ki se lahko kaže tudi z naslednjimi znaki in simptomi: epileptični napad, glavobol, spremenjeno duševno stanje, motnje vida ali kortikalna slepota s sočasno hipertenzijo ali brez nje.
Trial E2100 was an open-label, randomised, active controlled, multicentre clinical trial evaluating bevacizumab in combination with paclitaxel for locally recurrent or metastatic breast cancer in patients who had not previously received chemotherapy for locally recurrent and metastatic disease. 
Preskušanje E2100 je bilo odprto, randomizirano, z učinkovino nadzorovano multicentrično klinično preskušanje, v katerem so ocenjevali bevacizumab v kombinaciji s paklitakselom pri bolnikih z lokalno ponavljajočim se ali metastatskim rakom dojk, ki predhodno niso prejemali kemoterapije za lokalno ponavljajočo se ali metastatsko bolezen.
Eight hundred and thirteen patients were randomised to receive IFL + placebo (Arm 1) or IFL + bevacizumab (5 mg/kg every 2 weeks, Arm 2). 
Randomizirali so 813 bolnikov, ki so prejemali IFL + placebo (skupina 1) ali IFL + bevacizumab (5 mg/kg vsaka 2 tedna, skupina 2).
Cases of non-mandibular osteonecrosis have been observed in bevacizumab treated paediatric patients (see section 4.8, Paediatric population). 
pri zdravljenju pediatričnih bolnikov z bevacizumabom so opazili primere osteonekroze izven spodnje čeljustnice (glejte poglavje 4.8, ''Pediatrična populacija'')
Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and/or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. 
Primerne bolnice so imele dolgotrajen, ponavljajoči se ali metastatski ploščatocelični karcinom, adenoskvamozni karcinom ali adenokarcinom materničnega vratu, ki se ni odzival na kurativno zdravljenje s kirurškim posegom in/ali obsevanje, bolnice pa se predhodno še niso zdravile z bevacizumabom ali drugimi zaviralci VEGF oziroma tarčnimi zdravili za receptorje VEGF.
If the 60-minute infusion is well tolerated, all subsequent infusions may be administered over 30 minutes. 
Če bolnik dobro prenese tudi 60-minutno infuzijo, lahko vse naslednje infuzije dajemo 30 minut.
Topotecan+ Paclitaxel 
topotekan + paklitaksel
Combination of bevacizumab and sunitinib malate In two clinical trials of metastatic renal cell carcinoma, microangiopathic haemolytic anaemia (MAHA) was reported in 7 of 19 patients treated with bevacizumab (10 mg/kg every two weeks) and sunitinib malate (50 mg daily) combination. 
V 2 kliničnih preskušanjih pri bolnikih z metastatskim karcinomom ledvičnih celic so poročali o mikroangiopatični hemolitični anemiji (MAHA - microangiopathic haemolytic anaemia) pri 7 od 19 bolnikov, ki so se zdravili s kombinacijo bevacizumaba (10 mg/kg vsaka 2 tedna) in sunitinibijevega malata (50 mg na dan).
A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). 
Diagnozo PRES potrdimo s slikovnimi preiskavami možganov, po možnosti z magnetnoresonančnim slikanjem.
Overall response rate Rate (percent) 
Celokupni odziv delež (odstotki)
Overall survival Median (months) 
Celokupno preživetje mediana (meseci)
In clinical trials across indications, the overall incidence of venous thromboembolic reactions ranged from 2.8% to 17.3% of bevacizumab-treated patients compared with 3.2% to 15.6% in the control arms. 
V kliničnih preskušanjih pri vseh indikacijah je celokupna pojavnost venskih trombemboličnih dogodkov znašala od 2,8 % do 17,3 % pri bolnikih, ki so se zdravili z bevacizumabom, v primerjavi s 3,2 % do 15,6 % v kontrolnih skupinah.
In study BO20924 of bevacizumab with current standard of care in rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma, the safety profile of bevacizumab treated children was comparable with that observed in adults treated with bevacizumab. 
V študiji BO20924 z bevacizumabom v kombinaciji s trenutno standardno oskrbo rabdomiosarkoma in drugih vrst sarkoma mehkega tkiva je bil varnostni profil bevacizumaba pri otrocih, ki so se zdravili z bevacizumabom, primerljiv z varnostnim profilom pri odraslih, ki so se zdravili z bevacizumabom.
For patients in study AVF3694g who received anthracyclines concomitantly with bevacizumab, the incidences of Grade 3 or higher CHF for the respective bevacizumab and control arms were similar to those in the other studies in metastatic breast cancer: 2.9% in the anthracycline + bevacizumab arm and 0% in the anthracycline + placebo arm. 
V študiji AVF3694g je bila pri bolnikih, ki so prejemali antracikline sočasno z bevacizumabom, pojavnost KSP 3. ali višje stopnje v skupini z bevacizumabom in v kontrolni skupini podobna kot v drugih študijah metastatskega raka dojk: 2,9 % v skupini z antraciklini in bevacizumabom ter 0 % v skupini z antraciklini in placebom.
Zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. 
Zdravilo Zirabev je v kombinaciji z interferonom alfa-2a indicirano za prvo linijo zdravljenja odraslih bolnikov z napredovalim in/ali metastatskim rakom ledvičnih celic.
In addition, in study AVF3694g the incidences of all Grade CHF were similar between the anthracycline + bevacizumab (6.2%) and the anthracycline + placebo arms (6.0%). 
Dodatno so bile v študiji AVF3694g pojavnosti KSP vseh stopenj v skupini z antraciklini in bevacizumabom (6,2 %) podobne tistim v skupini z antraciklinom in placebom (6,0 %).
Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine, peripheral sensory neuropathy with paclitaxel or oxaliplatin, nail disorders or alopecia with paclitaxel, and paronychia with erlotinib. 
Primeri vključujejo sindrom palmarno-plantarne eritrodisestezije pri uporabi s pegiliranim liposomalnim doksorubicinom ali kapecitabinom, periferno senzorično nevropatijo pri uporabi s paklitakselom ali oksaliplatinom, bolezni nohtov ali alopecijo pri uporabi s paklitakselom in paronihijo pri uporabi z erlotinibom.
Patients who develop GI-vaginal fistulae may also have bowel obstructions and require surgical intervention as well as diverting ostomies. 
Bolnice, ki se jim pojavijo fistule med prebavili in nožnico, imajo lahko tudi obstrukcijo črevesa ter potrebujejo kirurški poseg in derivacijske stome.
Permanently discontinue Zirabev in patients with tracheoesophageal (TE) fistula or any Grade 4 fistula [US National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v.3)]. 
Pri bolnikih s traheoezofagealno fistulo ali katerokoli fistulo stopnje 4 [Merila NCI za poenoteno terminologijo neželenih učinkov, različica 3.0 (NCI-CTCAE v.3 - US National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0)] trajno prekinite zdravljenje z zdravilom Zirabev.
Response rates (for patients with measurable disease) 
Stopnje odziva (pri bolnikih z merljivo boleznijo) Ocena raziskovalca
In a study of platinum-resistant recurrent ovarian cancer patients, alopecia, mucosal inflammation, peripheral sensory neuropathy, proteinuria and hypertension were also reported and occurred at a rate at least 5% higher in the CT + BV arm for bevacizumab-treated patients ≥ 65 years of age compared with bevacizumab-treated patients aged < 65 years. 
V študiji pri bolnicah s ponavljajočim se rakom jajčnikov, odpornim proti platini, so poročali tudi o alopeciji, vnetju sluznic, periferni senzorični nevropatiji, proteinuriji in hipertenziji, ki so se v skupini, ki je prejemala kemoterapijo in bevacizumab, pojavili z najmanj 5 % večjo pogostnostjo pri bolnicah, starih ≥ 65 let, ki so se zdravile z bevacizumabom, v primerjavi z bolnicami, starimi < 65 let, ki so se ravno tako zdravile z bevacizumabom.
A third group of 33 patients received bolus 5-FU/FA + bevacizumab (10 mg/kg every 2 weeks). 
Tretja skupina 33 bolnikov je prejemala bolus 5-FU/FA + bevacizumab (10 mg/kg vsaka 2 tedna).
Observed in pediatric population only 
Ta neželeni učinek so opazili samo pri pediatrični populaciji.
There is no relevant use of bevacizumab in the paediatric population in the indications for treatment of cancers of the colon, rectum, breast, lung, ovarian, fallopian tube, peritoneum, cervix and kidney. 
Bevacizumab ni namenjen za uporabo pri pediatrični populaciji pri indikacijah za zdravljenje raka debelega črevesa, danke, dojk, pljuč, jajčnikov, jajcevodov, peritoneja, materničnega vratu in ledvic.
Decreased neutrophil count, decreased white blood cell count and presence of urine protein may be associated with bevacizumab treatment. 
Zdravljenje z bevacizumabom je lahko povezano z zmanjšanjem števila nevtrofilcev, zmanjšanjem števila belih krvnih celic in prisotnostjo beljakovin v urinu.
Trial BO17704 was a randomised, double-blind phase III trial of bevacizumab in addition to cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with locally advanced (stage IIIb with supraclavicular lymph node metastases or with malignant pleural or pericardial effusion), metastatic or recurrent non-squamous NSCLC, who had not received prior chemotherapy. 
Preskušanje BO17704 je bilo randomizirano, dvojno slepo preskušanje 3. faze, v katerem so primerjali bevacizumab kot dodatek cisplatinu in gemcitabinu s placebom, cisplatinom in gemcitabinom pri bolnikih z lokalno napredovalim (stadij IIIb z metastazami v supraklavikularnih bezgavkah ali malignim plevralnim ali perikardialnim izlivom), metastatskim ali ponavljajočim se neploščatoceličnim NSCLC, ki predhodno niso prejemali kemoterapije.
Cases of ONJ have been reported in cancer patients treated with bevacizumab, the majority of whom had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk. 
Pri bolnikih z rakom, ki so se zdravili z bevacizumabom, so poročali o primerih osteonekroze čeljustnic; večina teh bolnikov se je predhodno ali sočasno zdravila z intravenskimi bisfosfonati, pri katerih je osteonekroza čeljustnic znano tveganje.
Caution should be exercised when Zirabev and intravenous bisphosphonates are administered simultaneously or sequentially. 
Pri sočasnem ali zaporednem dajanju zdravila Zirabev in intravenskih bisfosfonatov je potrebna previdnost.
Uncommon (≥ 0.1% to < 1%) reports of fistulae that involve areas of the body other than the gastrointestinal tract (e.g. bronchopleural and biliary fistulae) were observed across various indications. 
Občasno (≥ 0,1 % do < 1 %) so pri različnih indikacijah poročali o fistulah, ki so se v telesu pojavljale izven prebavil (npr. plevrobronhialna in biliarna fistula).
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in patients with hepatic impairment since the liver is not a major organ for bevacizumab metabolism or excretion. 
Preskušanj za proučevanje farmakokinetike bevacizumaba pri bolnikih z jetrno okvaro niso opravili, saj jetra niso pomemben organ za presnovo ali izločanje bevacizumaba.
Patients who have experienced a venous thromboembolic reaction may be at higher risk for a recurrence if they receive bevacizumab in combination with chemotherapy versus chemotherapy alone. 
Pri bolnikih, pri katerih se pojavi venski trombembolični dogodek, lahko obstaja povečano tveganje za ponovitev dogodka, če prejemajo bevacizumab v kombinaciji s kemoterapijo, kot pa če prejemajo samo kemoterapijo.
In some cases underlying intra-abdominal inflammation was present, either from gastric ulcer disease, tumour necrosis, diverticulitis, or chemotherapy-associated colitis. 
V nekaterih primerih je bilo prisotno spremljajoče vnetje v trebušni votlini zaradi ulkusne bolezni želodca, nekroze tumorja, divertikulitisa ali s kemoterapijo povezanega kolitisa.
Thromboembolism (arterial) 
b,d trombembolija (arterijska)
Zirabev will be administered together with a chemotherapy regimen containing platinum. 
Zdravilo Zirabev boste prejeli skupaj s kemoterapevtsko shemo, ki vsebuje platino.
Bevacizumab has not been shown to reduce your ability to drive or to use any tools or machines. 
Vpliv na sposobnost upravljanja vozil in strojev Za bevacizumab niso dokazali, da zmanjšuje sposobnost upravljanja vozil ali uporabe orodij oziroma strojev.
XELOX or XELOX + bevacizumab 
XELOX ali XELOX + bevacizumab oksaliplatin kapecitabin
The haemorrhagic reactions that have been observed in clinical trials were predominantly tumour-associated haemorrhage (see below) and minor mucocutaneous haemorrhage (e.g. epistaxis). 
Krvavitve, ki so jih opazili v kliničnih preskušanjih, so bile večinoma krvavitve, povezane s tumorjem (glejte spodaj), ter manjše kožne in sluznične krvavitve (na primer epistaksa).
The median age was 46.0 years (range: 20-83) in the Chemo alone group and 48.0 years (range: 22-85) in the Chemo+bevacizumab group; with 9.3% of patients in the Chemo alone group and 7.5% of patients in the Chemo+bevacizumab group over the age of 65 years. 
Mediana starost je bila 46,0 let (razpon: 20-83 let) v skupini, ki je prejemala samo kemoterapijo, in 48,0 let (razpon: 22-85 let) v skupini, ki je prejemala kemoterapijo + bevacizumab, pri čemer je bilo 9,3 % bolnic v skupini, ki je prejemala samo kemoterapijo, in 7,5 % bolnic v skupini, ki je prejemala kemoterapijo + bevacizumab, starejših od 65 let.
● It is possible that Zirabev may increase the risk of developing holes in the gut wall. 
● Možno je, da zdravilo Zirabev poveča tveganje za pojav predrtja črevesne stene.
Fatal outcome was reported in 0.8% of patients receiving bevacizumab compared to 0.5% in patients receiving chemotherapy alone. 
O smrtnem izidu so poročali pri 0,8 % bolnikov, ki so prejemali bevacizumab, v primerjavi z 0,5 % bolnikov, ki so prejemali samo kemoterapijo.
Zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. 
Zdravilo Zirabev je v kombinaciji s kemoterapijo na osnovi fluoropirimidina indicirano za zdravljenje odraslih bolnikov z metastatskim karcinomom debelega črevesa in danke.
Grade 4 hypertension (hypertensive crisis) occurred in up to 1.0% of patients treated with bevacizumab and chemotherapy compared to up to 0.2% of patients treated with the same chemotherapy alone. 
Hipertenzija stopnje 4 (hipertenzivna kriza) se je pojavila pri največ 1,0 % bolnikov, ki so se zdravili z bevacizumabom in kemoterapijo, v primerjavi z največ 0,2 % bolnikov, ki so se zdravili samo z enako kemoterapijo.
The overall mean age was 59.4 years; 56.6% of patients had an ECOG performance status of 0, 43% had a value of 1 and 0.4% had a value of 2. 
Celokupna povprečna starost je bila 59,4 leta; splošno stanje zmogljivosti po ECOG (Eastern Cooperative Oncology Group) so pri 56,6 % bolnikov ocenili z 0, pri 43 % z 1 in pri 0,4 % z 2. 15,5 % bolnikov je predhodno prejemalo obsevalno zdravljenje, 28,4 % pa kemoterapijo.
Hazard ratio (97.5% CI) 
razmerje ogroženosti (97,5 % IZ)
Zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. 
Zdravilo Zirabev je kot dodatek kemoterapiji na osnovi platine indicirano za prvo linijo zdravljenja odraslih bolnikov z inoperabilnim, napredovalim, metastatskim ali ponavljajočim se nedrobnoceličnim rakom pljuč, ki nima prevladujoče ploščatocelične histologije.
Other reactions with a higher frequency seen in patients over 65 were Grade 3-4 leucopenia and thrombocytopenia (NCI-CTCAE v.3); and all Grade neutropenia, diarrhoea, nausea, headache and fatigue as compared to those aged ≤ 65 years when treated with bevacizumab (see sections 4.4 and 4.8 under Thromboembolism). 
Drugi neželeni učinki z večjo pogostnostjo, ki so jih med zdravljenjem z bevacizumabom opazili pri bolnikih, starejših od 65 let, v primerjavi z bolniki, starimi ≤ 65 let, so bili levkopenija in trombocitopenija stopnje 3-4 (NCI-CTCAE v.3) ter nevtropenija, diareja, navzea, glavobol in utrujenost vseh stopenj (glejte poglavji 4.4 in 4.8., ''Trombembolija'').